99% Purity Ss31 Oxytocin Acetate Dsip Pinealon Cortagen Foxo4-Drinad Ghk-Cu HMG Prostamax Pnc-27 PE-22-28 Dihexa Testagen Vilon Livagen Cardiogen Raw
5 Inquiries
6233-83-6
Pharmaceutical Grade
99%
shenzhen
ZQ
1G
2027-03-26
Semaglutide
-
Product Description
-
Seller Information
-
Inquiry History
-
DescriptionECHEMI Editorial ReferenceOxytocin acetate is an analog of oxytocin, a hormone that stimulates the uterus during labor. It is synthesized by chemically conjugation oxytocin with acetic acid. The stability of this molecule has been proven to be higher than that of oxytocin. This drug demonstrates a stronger binding affinity for the oxytocin receptor, which may be attributed to its increased molecular weight. Additionally, oxytocin acetate has been observed to increase levels of growth factors and fatty acids in tissues when administered intramuscularly, while also stimulating neurotransmission. It exhibits a shorter onset latency and a longer duration of action compared to other analogs. Apart from its medical applications, oxytocin acetate can also serve as a disinfectant in cosmetic use and as an amide-forming agent in organic synthesis reactions.
White SolidBasic Info-
Product Name:
Oxytocin acetate
Other Name:Oxytocin Identification (15 mg) (COLD SHIPMENT REQUIRED);Orasthin Acetate;Oxytocin Monoacetate;Perlacton Acetate;Pitocin Acetate;Synpitan Acetate;Syntocinon Acetate;Uteracon Acetate
CAS No.:6233-83-6
Molecular Formula:C45H70N12O14S2
InChIKeys:DSZOEVVLZMNAEH-SIVBSZNNNA-N
Molecular Weight:1067.25
EC Number:228-347-5
Color/Form:White to off-white
HScode:2937190000
Categories:
Characteristics-
Critical Temperature & Pressure:
Store at -20°C
Research-
Class:
Angiotensin IV-derived oligopeptide / HGF-c-Met potentiator
Status:Research compound — Not FDA approved
Mechanism:A synthetic, orally active, blood-brain-barrier-permeable oligopeptide (Hexanoyl-Tyr-Ile-Ahx-NH₂) derived from angiotensin IV. Dihexa binds hepatocyte growth factor (HGF) with high affinity (Kd = 65 pM) and allosterically potentiates HGF activity at its receptor c-Met, promoting dendritic spinogenesis and synaptogenesis. In preclinical models it was reported to be seven orders of magnitude more potent than BDNF at promoting synapse formation. Note: the foundational 2014 paper (McCoy AT, et al. Neurobiol Learn Mem. 2014) was retracted in 2025.
EC50 (HGF Binding KD):65 pM
Activity note:Dihexa is an HGF potentiator, not a direct receptor agonist. It does not activate c-Met alone but markedly augments HGF-induced c-Met activation at low nanomolar HGF concentrations. Functional synaptogenic activity was reported at 10⁻¹°–10⁻⁻ M (original data now subject to retraction).
Source:Original report: McCoy AT, et al. Neurobiol Learn Mem. 2014;115:112-120 (retracted 2025). Benoist CC, et al. J Pharmacol Exp Ther. 2014;351(3):628-637.
Clinical Development:
References-
PubChem:UNII:Literature:
Benoist CC, et al. J Pharmacol Exp Ther. 2014 — HGF/c-Met mechanism; McCoy AT, et al. Neurobiol Learn Mem. 2014 — Synaptogenesis data (Retracted 2025); Athira Pharma: Fosgonimeton (prodrug) pipeline status
Disclaimer:Dihexa is NOT FDA-approved or EMA-approved as a medicine. It is a research compound only. The foundational 2014 paper describing its synaptogenic potency was retracted in 2025. Its phosphate prodrug fosgonimeton failed a Phase 2/3 Alzheimer’s trial (LIFT-AD, 2024). This listing is for industrial and laboratory research use only. It is not medical advice, a clinical recommendation, or an approved therapy description. Always verify regulatory status, purity, and intended use with the supplier and applicable authorities before purchase or use.
Hazard IdentificationClassification of the substance or mixture
Acute toxicity - Category 4, Oral
Reproductive toxicity, Category 1A
Hazardous to the aquatic environment, long-term (Chronic) - Category Chronic 4
GHS label elements, including precautionary statements
Pictogram(s)
Signal word Danger
Hazard statement(s) H302 Harmful if swallowed
H360 May damage fertility or the unborn child
H413 May cause long lasting harmful effects to aquatic life
Precautionary statement(s) Prevention P264 Wash ... thoroughly after handling.
P270 Do not eat, drink or smoke when using this product.
P203 Obtain, read and follow all safety instructions before use.
P280 Wear protective gloves/protective clothing/eye protection/face protection/hearing protection/...
P273 Avoid release to the environment.
Response P301+P317 IF SWALLOWED: Get medical help.
P330 Rinse mouth.
P318 IF exposed or concerned, get medical advice.
Storage P405 Store locked up.
Disposal P501 Dispose of contents/container to an appropriate treatment and disposal facility in accordance with applicable laws and regulations, and product characteristics at time of disposal.
Other hazards which do not result in classification
no data available
Handling and StoragePrecautions for safe handling
Handling in a well ventilated place. Wear suitable protective clothing. Avoid contact with skin and eyes. Avoid formation of dust and aerosols. Use non-sparking tools. Prevent fire caused by electrostatic discharge steam.
Conditions for safe storage, including any incompatibilities
Store the container tightly closed in a dry, cool and well-ventilated place. Store apart from foodstuff containers or incompatible materials.
-
-
Seller Information
-
Business Type:
Trader
-
Main Products:
Semaglutide
-
Location:
hangzhou
-
Payment Terms:
TT against copy of documents,D/P,L/C,TT against B/L draft before shipment
-
Average lead Time:
2
-
Total Annual Revenue:
$1 million-$2.5 million
-
Total Employees:
11-50
-
Year of Establishment:
2025
-
-
Inquiry History5 Inquiries
Country Product Purchase Quantity Date Posted
United States
Oxytocin Acetate
10 G Feb 5, 2025
Brunei
Oxytocin acetate
1 G Apr 23, 2026
Mexico
Oxytocin acetate
15 MG Aug 4, 2026
Mexico
Oxytocin acetate
5 MT Aug 4, 2026
United States
Oxytocin acetate
30 MG Sep 15, 2025 Post an enquiry for this product
Pls input...
Pls input...